Cooley advised the underwriters in the upsized initial public offering of Sagimet Biosciences, a clinical-stage biotechnology company, at $85 million. Goldman Sachs & Co., Cowen and Company and Piper Sandler & Co. acted as joint book-running managers for the offering, while JMP Securities acted as lead manager. Partners John McKenna, Natalie Karam and Denny Won led the Cooley team advising the underwriters.